SynthesisPrimary care respiratory journal : journal of the General Practice Airways Group2012
Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies.
Synthesis in Primary care respiratory journal : journal of the General Practice Airways Group, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Allergen-specific oral immunotherapy for peanut allergy.The Cochrane database of systematic reviews · 2012Pooled it
- Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial.The Journal of allergy and clinical immunology · 2013Trial
- Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study.The World Allergy Organization journal · 2020Article
- Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy.Therapeutic advances in vaccines and immunotherapy · 2019Article
- Recent advances in immunotherapy and vaccine development for peanut allergy.Therapeutic advances in vaccines · 2015Review
- Sublingual immunotherapy: World Allergy Organization position paper 2013 update.The World Allergy Organization journal · 2014Article
- Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014Article
- Diagnosis and management of food allergies: new and emerging options: a systematic review.Journal of asthma and allergy · 2014Review
- Developing therapies for peanut allergy.International archives of allergy and immunology · 2014Review
- Oral and sublingual immunotherapy for food allergy.The World Allergy Organization journal · 2014Review
- Article
- Can we produce true tolerance in patients with food allergy?The Journal of allergy and clinical immunology · 2013Review
- Oral immunotherapy for peanut allergy: an evidence-based medicine assessment.Primary care respiratory journal : journal of the General Practice Airways Group · 2012Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundAllergy to peanuts is associated with considerable morbidity and, in a minority of cases, mortality. Natural resolution to peanut allergy occurs in only a few cases, hence the need to find effective interventions. Peanut oral immunotherapy (OIT) is a potentially important new therapeutic development.
aimsTo assess the benefits and harms of OIT for peanut allergy.
methodsFourteen databases were searched for published reports and unpublished/in-progress studies. We included studies employing randomised controlled trial (RCT), quasi-RCT, controlled clinical trial, controlled before-and-after, interrupted time series, and case series designs.
resultsSix studies enrolling a total of 85 participants satisfied our inclusion criteria. All studies employed a case series design and were thus judged to be at high risk of bias. Overall, this body of evidence provided suggestive evidence that it is possible for many participants to increase their threshold dose for peanut exposure whilst receiving treatment. Adverse reactions were common and, whilst most of these were relatively minor, some were potentially life-threatening.
conclusionsOIT appears to be a potentially promising new therapy for the short- to medium-term management of carefully selected and monitored patients with peanut allergy. The effectiveness and cost-effectiveness of OIT - particularly over the longer term - need to be clearly established using more robust designs before its clinical use can be contemplated. Given the risk of triggering serious adverse reactions, OIT should not be administered outside clinical trial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.